HomeCompareBLUE vs JEPI

BLUE vs JEPI: Dividend Comparison 2026

BLUE yields 40.24% · JEPI yields 8.56%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLUE wins by $205.6K in total portfolio value
10 years
BLUE
BLUE
● Live price
40.24%
Share price
$4.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$234.9K
Annual income
$39,898.44
Full BLUE calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.56%
Share price
$55.65
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.3K
Annual income
$1,573.67
Full JEPI calculator →

Portfolio growth — BLUE vs JEPI

📍 BLUE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLUEJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLUE + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BLUE pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLUE
Annual income on $10K today (after 15% tax)
$3,420.52/yr
After 10yr DRIP, annual income (after tax)
$33,913.67/yr
JEPI
Annual income on $10K today (after 15% tax)
$727.38/yr
After 10yr DRIP, annual income (after tax)
$1,337.62/yr
At 15% tax rate, BLUE beats the other by $32,576.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLUE + JEPI for your $10,000?

BLUE: 50%JEPI: 50%
100% JEPI50/50100% BLUE
Portfolio after 10yr
$132.1K
Annual income
$20,736.05/yr
Blended yield
15.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BLUE right now

BLUE
Analyst Ratings
14
Buy
19
Hold
4
Sell
Consensus: Hold
Price Target
$13.69
+175.5% upside vs current
Range: $5.00 — $25.00
Altman Z
-23.5
Piotroski
3/9
JEPI
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLUE buys
0
JEPI buys
0
No recent congressional trades found for BLUE or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLUEJEPI
Forward yield40.24%8.56%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$234.9K$29.3K
Annual income after 10y$39,898.44$1,573.67
Total dividends collected$177.1K$12.0K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: BLUE vs JEPI ($10,000, DRIP)

YearBLUE PortfolioBLUE Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$14,724$4,024.14$11,276$855.74+$3.4KBLUE
2$21,292$5,537.58$12,675$926.02+$8.6KBLUE
3$30,267$7,483.95$14,207$999.01+$16.1KBLUE
4$42,328$9,942.36$15,878$1,074.57+$26.4KBLUE
5$58,285$12,994.66$17,697$1,152.57+$40.6KBLUE
6$79,088$16,723.03$19,674$1,232.87+$59.4KBLUE
7$105,832$21,207.24$21,815$1,315.29+$84.0KBLUE
8$139,762$26,521.85$24,131$1,399.68+$115.6KBLUE
9$182,279$32,733.51$26,630$1,485.86+$155.6KBLUE
10$234,937$39,898.44$29,323$1,573.67+$205.6KBLUE

BLUE vs JEPI: Complete Analysis 2026

BLUEStock

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Full BLUE Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this BLUE vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLUE vs SCHDBLUE vs OBLUE vs KOBLUE vs MAINBLUE vs JEPQBLUE vs XYLDBLUE vs DIVOBLUE vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.